Haohai Biological Reports Full-Year Income Retreat Amid VBP Pressures
Shanghai Haohai Biological Technology Co., Ltd. has reported a decline in full-year income for the 2025 fiscal year, driven by margin compression in its core ophthalmology and orthopedic segments. The retreat highlights the ongoing challenges of China's volume-based procurement (VBP) policies and intensifying competition in the medical aesthetics market.